Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) - Investment analysts at HC Wainwright reduced their Q2 2025 earnings per share (EPS) estimates for shares of Context Therapeutics in a note issued to investors on Thursday, May 8th. HC Wainwright analyst E. Bodnar now expects that the company will earn ($0.05) per share for the quarter, down from their prior forecast of ($0.04). HC Wainwright has a "Buy" rating and a $5.00 price target on the stock. The consensus estimate for Context Therapeutics' current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for Context Therapeutics' Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.06) EPS, FY2025 earnings at ($0.22) EPS, FY2026 earnings at ($0.34) EPS, FY2027 earnings at ($0.44) EPS, FY2028 earnings at ($0.48) EPS and FY2029 earnings at ($0.32) EPS.
Context Therapeutics (NASDAQ:CNTX - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.05).
CNTX has been the subject of a number of other reports. D. Boral Capital reiterated a "buy" rating and issued a $9.00 price objective on shares of Context Therapeutics in a report on Thursday, May 8th. William Blair reaffirmed an "outperform" rating on shares of Context Therapeutics in a research report on Tuesday, April 29th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Context Therapeutics currently has a consensus rating of "Buy" and an average target price of $5.40.
Get Our Latest Stock Analysis on CNTX
Context Therapeutics Trading Up 5.1%
NASDAQ:CNTX traded up $0.04 on Monday, hitting $0.82. 143,109 shares of the company's stock traded hands, compared to its average volume of 292,141. The firm has a 50-day moving average price of $0.78 and a 200-day moving average price of $1.10. Context Therapeutics has a 1 year low of $0.55 and a 1 year high of $2.75. The company has a market cap of $73.56 million, a PE ratio of -0.90 and a beta of 2.11.
Hedge Funds Weigh In On Context Therapeutics
Several large investors have recently bought and sold shares of the business. Jane Street Group LLC bought a new position in Context Therapeutics in the fourth quarter valued at approximately $29,000. Citadel Advisors LLC bought a new stake in shares of Context Therapeutics during the 4th quarter valued at $31,000. Shay Capital LLC acquired a new stake in Context Therapeutics during the fourth quarter worth about $52,000. Clear Harbor Asset Management LLC increased its stake in Context Therapeutics by 60.6% in the fourth quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company's stock valued at $61,000 after acquiring an additional 21,804 shares during the last quarter. Finally, Landscape Capital Management L.L.C. acquired a new position in shares of Context Therapeutics during the 4th quarter worth $94,000. 14.03% of the stock is currently owned by institutional investors and hedge funds.
About Context Therapeutics
(
Get Free Report)
Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Read More
Before you consider Context Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Context Therapeutics wasn't on the list.
While Context Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
